Table 2.
Correlation of tumour entity and CCL20 expression.
| # of cases* | CCL20low [%] | CCL20high [%] | P value | |
|---|---|---|---|---|
| Total | 334 | 0.004 | ||
| pT1 | 15 | 46.7 | 53.3 | |
| pT2 | 111 | 31.5 | 68.5 | |
| pT3 | 157 | 16.6 | 83.4 | |
| pT4 | 51 | 31.4 | 68.6 | |
| Total | 338 | 0.048 | ||
| pN0 | 219 | 27.9 | 72.1 | |
| pN1 | 64 | 15.6 | 84.4 | |
| pN2 | 50 | 20.0 | 80.0 | |
| pN3 | 5 | 60.0 | 40.0 |
*Tissue microarrays of colon carcinoma (n = 213), breast cancer (n = 73) and HNSCC (n = 48) were analyzed for CCL20 expression. Expression data were correlated to TNM values (T = tumour size, N = degree of spread to regional lymph nodes) and statistically analyzed by Pearson’s Chi-Square test.